CMS is setting standards for what cannabinoid medicine looks like

(This is a contributed guest column. To be considered as an MJBizDaily guest columnist, please submit your request here.)

Alleh Lindquist (courtesy photo)

When the Substance Access Beneficiary Engagement Incentive (BEI) launched in April, much of the cannabis and hemp industry treated it as a broad Medicare reimbursement story. It is not.

The Centers for Medicare & Medicaid Services (CMS) created something narrower and more consequential: a clinician-guided pathway inside select value-based care models where eligible hemp-derived products can be furnished to eligible beneficiaries at the participating organization’s expense, with safeguards, implementation-plan requirements and clinical oversight.

That distinction matters. BEI is not a retail opportunity wearing a healthcare label. It is an early test of whether hemp-derived products can meet the standards of accountable care: documentation, consistency, safety, clinician confidence and measurable impact on patient outcomes and downstream cost.

How does the BEI pilot actually work?

Medicare does not pay for the products, and beneficiaries do not submit claims. Under the Substance Access BEI, eligible Innovation Center model participants may furnish eligible hemp-derived products to beneficiaries at no cost, up to $500 per eligible beneficiary per year, if they elect the incentive and receive CMS approval for their implementation plan.

The implementation plan must identify the products, dosing information, distribution frequency, beneficiary eligibility criteria, safeguards and oversight procedures. This is not CMS approval of a product for the broader market. It is a model-specific pathway for certain participants under defined conditions.

The eligible product category is narrow, but it does not exclude all THC. Products must be federally legal hemp-derived products containing no more than 0.3% delta-9 THC, comply with applicable law and meet CMS quality and safety requirements, including third-party testing.

The framework excludes inhalable products, orally administered products containing more than 3 mg per serving of tetrahydrocannabinols and products containing cannabinoids not naturally produced, or capable of being produced, by the cannabis plant.

The incentive is also clinician-led. A physician or other qualified clinician must determine that the product is appropriate and document shared decision-making, including risks, benefits, medication review, potential interactions, patient goals and follow-up.

That structure changes what matters. In retail, a product can win with brand, price and access. In a physician-led value-based care channel, the product must be standardized, documentable, clinically rational and safe enough for medically complex patients and risk committees responsible for outcomes and cost.

Does BEI create a new framework for sanctioned use?

The BEI program changes the cannabinoid conversation because it creates something distinct from the existing market: a federally sanctioned framework for eligible hemp-derived products to be used inside select healthcare models.

That matters because today’s hemp cannabinoid market is commercially active and legal in many contexts under the federal hemp definition, but commercial legality is not the same as federal approval for human consumption. The traditional federal pathways remain Generally Recognized As Safe (GRAS) for food ingredients, New Dietary Ingredient notifications for dietary supplements and the Food and Drug Administration (FDA) drug approval pathway, which has already been used for the seizure drug Epidiolex.

BEI does not replace those pathways or approve products for general sale. It creates a narrow healthcare context where eligible hemp-derived products can be furnished under clinician guidance, model requirements and applicable law.

That changes the standard. A product that is legal to sell is not automatically ready for healthcare adoption. In this channel, products will be judged on evidence, standardization, safety, manufacturing controls, clinician usability and real-world outcomes.

Adoption starts with ACOs and ends with clinicians

The biggest question is not whether BEI allows eligible hemp-derived products into certain care models. It does.

The real question is whether Accountable Care Organizations (ACOs) and other eligible participants will adopt the program, identify qualifying products and include them in their implementation plans.

That decision starts with cost of care. In value-based care, ACOs need to understand whether structured cannabinoid use can improve outcomes while reducing avoidable downstream costs tied to chronic pain, poor sleep, anxiety, medication burden, fall risk and unnecessary use.

But ACO adoption is only the first gate. Clinicians are the next. They will not recommend or furnish products simply because a federal model allows them to. They will ask what the product is, what dose is appropriate, how consistent it is, what safety data exists, what medications it may interact with and which patients are appropriate.

The regulatory opening may remove one barrier, but this channel has multiple gatekeepers. ACOs need to see a cost-of-care rationale, implementation teams need products that can be documented and monitored, and clinicians need enough confidence to discuss them with patients at the point of care.

What should operators and investors understand now?

For operators and manufacturers, the window to position for institutional channels is open, but it will not remain undefined forever. The current BEI requirements create a pathway. They do not create a durable competitive advantage.

The advantage will belong to companies that build beyond minimum eligibility: clinical research, standardized dosing, toxicology data, quality systems, physician-facing documentation, medication review workflows, adverse event tracking and real-world evidence.

This is the standard FloraWorks has been building toward. A randomized controlled trial may not be a formal CMS requirement today, but it may become the practical minimum for a serious physician conversation. A certificate of analysis can show what is in the bottle. It does not show how a clinician should use it.

BEI will likely start small. Most meaningful healthcare innovation does. But if the model works, it could mark a turning point – not because Medicare reimbursed cannabis but because CMS created a structure where eligible hemp-derived products can begin proving whether they belong inside accountable care.

That is the real story. The next phase of the cannabinoid market will not be built around access alone. It will be built around evidence, safety, documentation and outcomes. Companies that invested early in those foundations will help define what healthcare-grade cannabinoids look like.

Alleh Lindquist is the co-founder and CEO of FloraWorks, which focuses on the research and development of rare cannabinoids.